<DOC>
	<DOCNO>NCT00001061</DOCNO>
	<brief_summary>To evaluate effect MSL 109 , human monoclonal anti-cytomegalovirus ( CMV ) antibody , time progression CMV retinitis . To determine safety pharmacokinetic profile MS 109 . To evaluate relationship pharmacokinetic measurement MSL 109 efficacy virologic marker . Therapeutic agent currently available CMV retinitis limit inherent toxicity short half-lives require frequent intravenous dose . Alternatively , MSL 109 demonstrate safety effectiveness neutralize CMV isolates concentration easily maintain AIDS patient .</brief_summary>
	<brief_title>Comparison Two Methods Treatment Cytomegalovirus Eyes Patients With AIDS</brief_title>
	<detailed_description>Therapeutic agent currently available CMV retinitis limit inherent toxicity short half-lives require frequent intravenous dose . Alternatively , MSL 109 demonstrate safety effectiveness neutralize CMV isolates concentration easily maintain AIDS patient . Patients receive induction therapy intravenous ganciclovir foscarnet daily 14 day , place standard maintenance therapy induction drug least 11 month progression . Patients randomize receive 1 2 dos MLS 109 placebo every 2 week induction maintenance . They follow week 2 4 every 4 week thereafter 40 week . Patients progress week 40 continue study drug follow-up every 2 month CMV progression occur . AS PER AMENDMENT 11/29/96 : Enrollment onto current study discontinue . To study enhancement humoral immunity , high-dose cohort add . Patients randomize MSL 109 give high dose placebo administer interval . Randomization weight 2:1 favor high-dose MSL 109 . Interim analysis perform provide early discontinuation , indicate . Patients randomize early version may continue original study assignment study endpoint reach .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Retinitis</mesh_term>
	<mesh_term>Cytomegalovirus Retinitis</mesh_term>
	<mesh_term>Ganciclovir</mesh_term>
	<mesh_term>Foscarnet</mesh_term>
	<mesh_term>Phosphonoacetic Acid</mesh_term>
	<mesh_term>Ganciclovir triphosphate</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : GCSF GMCSF . Antiretroviral therapy . Patients must : HIV infection . First episode CMV retinitis . No prior endorgan CMV disease PER AMENDMENT 4/25/96 : No prior end organ CMV disease within past 6 month . Subjects prophylaxed oral ganciclovir develop episode CMV retinitis eligible . No active AIDSdefining opportunistic infection malignancy require nephrotoxic myelosuppressive therapy . Life expectancy least 6 month . Consent parent guardian le 18 year age . NOTE : This protocol approve prisoner participation . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : PER AMENDMENT 4/25/96 : Retinal detachment schedule surgical repair , eye meet eligibility criterion . ( Was write No current retinal detachment ( although old retinal detachment unrelated HIV infection repair permit ) . Corneal , lens , vitreous opacification precludes funduscopic exam . Clinically significant pulmonary neurologic impairment , intubation coma . ( Patients CNS mass history seizure disorder may enroll . ) Tuberculous , diabetic , hypertensive retinopathy , retinal lesion would interfere measurement response progression . Known hypersensitivity study drug . PER AMENDMENT 4/25/96 : Presence CMV retinal lesion area retina photograph . Concurrent Medication : Excluded : Immunomodulators , biologic response modifier , interferon , investigational agent may influence course CMV infection . Systemic acyclovir nephrotoxic agent , specifically aminoglycosides , amphotericin B , parenteral pentamidines . Any concomitant therapy would preclude use cidofovir , foscarnet ganciclovir . Prior Medication : Excluded : PER AMENDMENT 4/25/96 : Use IV ganciclovir , foscarnet cidofovir within 6 month prior study enrollment . ( Was write Ganciclovir foscarnet nonCMV herpes infection within 6 month prior study entry . )</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Ganciclovir</keyword>
	<keyword>Foscarnet</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>Antibodies , Monoclonal</keyword>
	<keyword>Cytomegalovirus Retinitis</keyword>
</DOC>